Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This study found that among patients with sex cord stromal ovarian tumors, 11% exhibited signs of virilization, requiring thorough clinical evaluation to rule out non-neoplastic causes.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

This case study in a 62-year-old postmenopausal woman highlights Leydig cell hyperplasia as a likely cause of hyperandrogenism of ovarian origin, where bilateral oophorectomy resolved the condition and confirmed the diagnosis through histopathological examination.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This article reviews topics from the American Academy of Veterinary Dermatology and American College of Veterinary Dermatology Annual Meeting and contains no new clinical findings.

This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.

In this study, researchers found that fenugreek seed extract reduced prostate size, DHT levels, and cell proliferation in a testosterone-induced BPH rat model while modulating various genetic expressions, suggesting its potential as an alternative treatment for benign prostatic hyperplasia.

This study found that inhibiting AP-1 transcription factors in mice causes squamous tumors to transform into sebaceous tumors and regulates tumor cell lineage.

This study found that inhibiting AP-1 activity in mice can induce lineage transdifferentiation between squamous and sebaceous tumors, suggesting AP-1's role in maintaining tumor cell identity.

This chapter reviews genetic defects in female sexual differentiation, focusing on 46,XX disorders of sex development and the impact of genetic factors and sex steroids on development, but reports no new clinical findings.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

A gene mutation in mice causes increased mast cells and disorganized hair follicles in their skin.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This review discusses the role of the TOR pathway in aging and suggests that rapamycin could potentially target age-related diseases, but reports no new clinical results.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review discusses the diagnosis and treatment of hirsutism, emphasizing that a systematic evaluation can determine its cause, while combination therapy effectively manages the condition for most patients.